A Study of the Clinical Activity and Safety of JNJ-64041809, a Live Attenuated Listeria Monocytogenes Immunotherapy, in Combination With Apalutamide Versus Apalutamide in Subjects With Metastatic Castration-resistant Prostate Cancer
Condition: Prostatic Neoplasms, Castration-Resistant Interventions: Drug: JNJ-809; Drug: Apalutamide Sponsor: Janssen Research & Development, LLC Not yet recruiting - verified September 2016
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer | Cancer & Oncology | Immunotherapy | Listeria | Prostate Cancer | Research | Study